ReproCELL

Symic Biomedical is a biotechnology company based in San Francisco, California, focusing on developing matrix regulator therapeutics. These therapeutics are designed to target and bind to specific sites within the body's extracellular matrix that have been damaged due to injury or disease. By inhibiting pathological inflammatory responses, Symic Biomedical aims to address conditions such as fibrosis, oncology, and diseases of the central nervous system. The company was incorporated in 2012 and operates as a subsidiary of Symic Holdings, LLC.

BioServe Biotechnologies (India) Pvt Ltd, established in 1994 and based in Hyderabad, specializes in DNA extraction, synthesis, sequencing, and related molecular services. As a pioneer in the Indian biotechnology sector, the company provides a comprehensive suite of research tools aimed at enhancing advancements in genetics, drug discovery, biomarker research, and molecular diagnostics. Its offerings include next-generation sequencing, biomarker discovery, GMO testing, and various molecular biology kits designed for both research and educational purposes. Recognized as a DSIR laboratory, BioServe holds ISO9001-2008 and NABL accreditation, ensuring high-quality standards in its operations. The company serves a wide range of clients, including numerous institutes under the Indian Council of Medical Research and the Council of Scientific and Industrial Research, alongside major pharmaceutical and biotechnology firms.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company specializes in the research and development of hepatocyte growth factor (HGF) protein medicines, which have regenerative healing properties for liver cells and other organs. Kringle Pharma focuses on creating HGF products aimed at treating a range of conditions, including acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury associated with ALS, and vocal fold scars. Additionally, the company explores the therapeutic potential of NK4, a bi-functional molecule that acts as an HGF-antagonist with antiangiogenic properties, targeting cancer therapies. Kringle Pharma's innovative approach positions it at the forefront of developing treatments for intractable diseases.

Biopta Ltd. is a contract research organization based in Glasgow, United Kingdom, specializing in human tissue-based services for the pharmaceutical industry. Founded in 2002, the company utilizes ethically donated residual human tissue from surgeries to predict drug activity prior to clinical trials. Biopta provides a range of services, including laboratory and comparative pharmacology, clinical biopsies, and both in-vitro and ex-vivo techniques. Their expertise spans several therapeutic areas, offering services related to cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary functions. In addition, Biopta maintains a catalogue of human functional tissue assays, which includes various standard assays. The organization operates laboratories in Glasgow and Maryland and functions as a subsidiary of ReproCELL, Inc. since December 2015.

Reinnervate Limited is a biotechnology company based in Durham, United Kingdom, established in 2002. It specializes in the development of technologies that enhance research into cell growth and function in vitro, with a particular focus on stem cell biology. The company creates and markets 3D cell-culture products that enable researchers to establish assays and biological models that closely simulate in-vivo cell growth. Reinnervate's innovations also facilitate the control of stem cell differentiation and the formation of specific tissue types, contributing to the development of diagnostics and treatments for neuro-degenerative diseases.